PF-Atlas › Clinical Trials › NCT02345070
Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis
SAR156597 · Phase 2
Registry ID
NCT02345070
Phase
Phase 2
Status
Completed
Drug / intervention
SAR156597
Sponsor
Sanofi
Start
2015-05-01
Enrollment
327
Locations
101
About this trial
Primary Objective: To evaluate, in comparison with placebo, the efficacy of 2 dose levels/regimens of SAR156597 administered subcutaneously during 52 weeks on lung function of participants with Idiopathic Pulmonary Fibrosis (IPF). Secondary Objectives: To evaluate the efficacy of 2 dose levels/regimens of SAR156597 compared to placebo on IPF disease progression. To evaluate the safety of 2 dose levels/regimens of SAR156597 compared to placebo in participants with IPF.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT02345070 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.